Skip to main content
. 2023 Jul 6;14(9):1517–1535. doi: 10.1007/s13300-023-01438-w

Fig. 3.

Fig. 3

Proportion of patients who achieved the composite endpoint stratified by baseline BMI (A), age (B), or eGFR (C). The proportion of patients who achieved the composite endpoint was compared between the luseogliflozin and DPP-4i groups using the Chi-squared test. Asterisks indicate a significant difference between groups at *p < 0.05, **p < 0.01, and ***p < 0.001. BMI Body mass index